GA
RYTM icon

Greenspring Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Greenspring Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-7,175
Closed -$196K – 12
2019
Q1 		$196K Buy
+7,175
New +$206K 0.08% 8

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Greenspring Associates's RYTM Position: Q2 2019 in Review

Greenspring Associates sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2019, closing a stake of 7,175 shares — an estimated $196K sold.

Greenspring Associates first reported a position in RYTM in Q1 2019 and held it in 1 quarter. The position peaked at $196K in Q1 2019. 84 funds tracked by Wall St. Rank hold RYTM as of Q2 2019.

  • Greenspring Associates reported no remaining Rhythm Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Greenspring Associates sold 7,175 Rhythm Pharmaceuticals shares in Q2 2019, an estimated $196K.
  • Greenspring Associates first reported a position in Rhythm Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Greenspring Associates's Rhythm Pharmaceuticals position peaked at $196K in Q1 2019.
  • 84 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2019.

Based on Greenspring Associates's 13F filing for Q2 2019, filed 14 Feb 2020.